Preview

PDF Pending copyright assessment - Request a copy 1Mb

Currently, there is no consensus on whether a standard 2-g prophylactic cefazolin dose provides sufficient antimicrobial coverage in obese surgical patients. This systematic review analysed both outcome and pharmacokinetic studies, aiming to determine the appropriate cefazolin dose. A systematic search was conducted using 4 databases. In total, 3 outcome and 15 pharmacokinetic studies met the inclusion criteria. All 3 outcome studies concluded that there is no need for increased dose. Also, 9 pharmacokinetic studies reached this conclusion; however, 6 pharmacokinetic studies recommended that 2-g dose is insufficient to achieve adequate plasma or tissue concentrations. The stronger body of evidence supports that 2-g dose of cefazolin is sufficient for surgery lasting up to 4 h; however, large-scale outcome studies are needed to confirm this evidence.

Item Type:	Refereed Article
Keywords:	obesity, cefazolin, dosing, surgical site infection, prophylaxis
Research Division:	Biomedical and Clinical Sciences
Research Group:	Pharmacology and pharmaceutical sciences
Research Field:	Clinical pharmacology and therapeutics
Objective Division:	Health
Objective Group:	Clinical health
Objective Field:	Efficacy of medications
UTAS Author:	Peterson, GM (Professor Gregory Peterson)
ID Code:	150996
Year Published:	2022
Deposited By:	Pharmacy
Deposited On:	2022-07-10
Last Modified:	2022-07-25
Downloads:	0